1-9 of 9
Kelly Zullo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1280.
https://doi.org/10.1182/blood.V126.23.1280.1280
Published: 2015
Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD
Journal: Blood
Blood (2015) 126 (23): 1282.
https://doi.org/10.1182/blood.V126.23.1282.1282
Published: 2015
Journal Articles

The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)

Luigi Scotto, PhD, Xavier Jirau-Serrano, BS, Kelly Zullo, MS, Michael Mangone, PhD, Jennifer E Amengual, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3703.
https://doi.org/10.1182/blood.V126.23.3703.3703
Published: 2015
Journal Articles

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Kelly Zullo, MS, Yige Guo, PhD, Laurence Cooke, B.A., Xavier Jirau Serrano, BS, Michael Mangone, PhD, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Daruka Mahadevan, MD PhD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4493.
https://doi.org/10.1182/blood.V124.21.4493.4493
Published: 2014
Journal Articles

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Jennifer E Amengual, MD, Paul M. Johannet, BA, Kelly Zullo, MS, Maximilian Lombardo, MS, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1777.
https://doi.org/10.1182/blood.V124.21.1777.1777
Published: 2014
Journal Articles

The HDACi Romidepsin Markedly Synergizes With Inhibition Of ATM By KU60019 In Mantle Cell Lymphoma

Luigi Scotto, PhD, Kelly Zullo, BS, Xavier Jirau Serrano, BS, Laura K Fogli, MS, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3066.
https://doi.org/10.1182/blood.V122.21.3066.3066
Published: 2013
Journal Articles

The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib

Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 5141.
https://doi.org/10.1182/blood.V122.21.5141.5141
Published: 2013
Journal Articles

The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma

Owen A. O'Connor, MD, PhD, Enrica Marchi, MD, PhD, Kelly Zullo, BS, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Fabio Fuligni, Pier Luigi Zinzani, MD, Stefano A. Pileri, Pier Paolo Piccaluga, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 646.
https://doi.org/10.1182/blood.V122.21.646.646
Published: 2013
Journal Articles

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Jennifer E. Amengual, MD, Paul M Johannet, Xavier Jirau-Serrano, BS, Kelly Zullo, BS, Daniela Hoehn, MD, PhD, Govind Bhagat, MD, Maximilian Lombardo, B.S., Luigi Scotto, PhD, Simon S Jones, PhD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 648.
https://doi.org/10.1182/blood.V122.21.648.648
Published: 2013